Future research should integrate data on Aβ deposition, tau accumulation, and NfL levels with blood‐based biomarkers and should stratify or adjust for key confounders such as body mass index, comorbidities (e.g., diabetes, cardiovascular disease), and medications. Here, NEFL is linked to cardiovascular disorder.